Medications

Anti-VEGF therapy may aid visual acuity in some nAMD patients

(HealthDay)—For about 20 percent of patients with neovascular age-related macular degeneration (nAMD), useful visual acuity (VA) is preserved with anti-vascular endothelial growth factor (VEGF) treatment, according to a ...

Ophthalmology

Quarter of partially-sighted have unmet needs

Almost a quarter of people with severe sight loss in the UK are going without the treatment they need, according to a new study being presented at the World Congress on Public Health today.

Ophthalmology

Blindness in the elderly: Finally a treatment in the near future?

The macula accounts for sharp vision and reading but it is affected in many elderly. Age related macular degeneration is the most important cause of blindness in persons over 65 years of age, and almost 30% of people over ...

Immunology

Imaging the secret lives of immune cells in the eye

University of Rochester vision scientist Jesse Schallek can barely contain his excitement as he shares time-lapse videos showing immune cells moving through living retinal tissue at the back of an eye.

Ophthalmology

Blindness and sight loss to double by 2050

Blindness and severe vision impairment is predicted to affect almost 900 million people worldwide by 2050—up from around 338 million today, according to a new pre-print study accepted by The Lancet and highlighted on World ...

page 1 from 2